BDBM404256 (1 2-{3-[(3R,6R)-6-Methyl-1-{[2-(2H-1,2,3-triazol-2-yl)phenyl]carbonyl}piperidin-3-yl]isoxazol-5-yl}propan-2-ol)::US10017504, 1

SMILES C[C@@H]1CC[C@H](CN1C(=O)c1ccccc1-n1nccn1)c1cc(on1)C(C)(C)O

InChI Key InChIKey=DNGHIQGLHKSAIM-UHFFFAOYSA-N

Data  2 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 2 hits for monomerid = 404256   

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM404256((1 2-{3-[(3R,6R)-6-Methyl-1-{[2-(2H-1,2,3-triazol-...)
Affinity DataIC50: 46.9nMAssay Description:n a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM404256((1 2-{3-[(3R,6R)-6-Methyl-1-{[2-(2H-1,2,3-triazol-...)
Affinity DataIC50: 1.00E+4nMAssay Description:n a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
US Patent